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and Hypermanganesemia Caused by Mutations
in SLC30A10, a Manganese Transporter in Man
Karin Tuschl,1,* Peter T. Clayton,1 Sidney M. Gospe, Jr.,2 Shamshad Gulab,3 Shahnaz Ibrahim,3
Pratibha Singhi,4 Roosy Aulakh,5 Reinaldo T. Ribeiro,6 Orlando G. Barsottini,6 Maha S. Zaki,7
Maria Luz Del Rosario,8 Sarah Dyack,9 Victoria Price,9 Andrea Rideout,9 Kevin Gordon,9
Ron A. Wevers,10 W.K. ‘‘Kling’’ Chong,11 and Philippa B. Mills1
Environmental manganese (Mn) toxicity causes an extrapyramidal, parkinsonian-type movement disorder with characteristic magnetic
resonance images of Mn accumulation in the basal ganglia. We have recently reported a suspected autosomal recessively inherited
syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia in cases without environmental Mn exposure.
Whole-genome mapping of two consanguineous families identified SLC30A10 as the affected gene in this inherited type of hyperman-
ganesemia. This gene was subsequently sequenced in eight families, and homozygous sequence changes were identified in all affected
individuals. The function of the wild-type protein and the effect of sequence changes were studied in the manganese-sensitive yeast
strain Dpmr1. Expressing human wild-type SLC30A10 in the Dpmr1 yeast strain rescued growth in high Mn conditions, confirming
its role in Mn transport. The presence of missense (c.266T>C [p.Leu89Pro]) and nonsense (c.585del [p.Thr196Profs*17]) mutations
in SLC30A10 failed to restore Mn resistance. Previously, SLC30A10 had been presumed to be a zinc transporter. However, this work
has confirmed that SLC30A10 functions as aMn transporter in humans that, when defective, causesMn accumulation in liver and brain.
This is an important step toward understanding Mn transport and its role in neurodegenerative processes.Introduction
Manganese (Mn) is an essential tracemetal that plays a crit-
ical role as a cofactor for a variety of enzymes involved in
amino acid, lipid and carbohydrate metabolism, immune
function, bone and connective tissue growth, and blood
clotting.1 The main source of Mn in humans is through
dietary ingestion. Stable tissue levels are maintained by
tight homeostatic control of intestinal absorption and
biliary excretion of Mn.2 Although Mn is critical for cell
function, overexposure is known to be neurotoxic and
causes ‘‘manganism.’’ This distinct syndrome of extrapyra-
midal movement disorder combined with high signal
intensity of the basal ganglia on T1-weighted magnetic
resonance images (MRI) of the brain is caused by Mn accu-
mulation in the basal ganglia.3,4
Most frequently, hypermanganesemia occurs because of
environmental overexposure. It has been described in
workers in mining and welding industries who inhale
Mn-laden dust or fumes3,5,6 and in individuals ingesting
contaminated drinking water.7 However, cases of Mn
intoxication have also been observed in drug addicts
who use intravenous methcathinone contaminated with
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The Amereceiving parenteral nutrition.10,11 Acquired hepatocere-
bral degeneration (AHD) can develop in individuals with
impaired biliary excretion of Mn including those with
advanced hepatic cirrhosis or portosystemic shunts
causing a debilitating motor disorder.12–15 Predisposition
to Mn toxicity has also been suggested in individuals
with idiopathic Parkinson’s disease (PD).16,17 Indeed, it
has been reported that the use of methylcyclopentadienyl
manganese tricarbonyl (an organic derivative of Mn) as an
octane enhancer in gasoline might result in earlier presen-
tation of PD.18 Although manganism resembles PD (with
symptoms of generalized bradykinesia and rigidity), there
are characteristic features distinguishing Mn intoxication
from idiopathic PD. Manganism more frequently causes
dystonia, shows poor therapeutic response to levodopa,
and has normal fluorodopa uptake by PET scan.19,20
Several cases of hypermanganesemia, dystonia, and
polycythemia with a variable degree of hepatic dysfunc-
tion have been described in children without significant
environmental Mn exposure.21–26 Identification of two
affected siblings, from a consanguineous family, with this
disorder suggested an inherited defect of Mn homeostasis
[MIM 613280].21 We have identified a further 13 individ-
uals from seven families with similar symptoms, some off Child Health, London, WC1N 1EH, UK; 2Departments of Neurology and
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them previously reported,22–24 and performed homozy-
gosity mapping to identify the affected gene. Affected indi-
viduals carry mutations in SLC30A10 [MIM 611146],
solute carrier family 30, member 10, a previously presumed
zinc (Zn) transporter. The effects of sequence changes were
investigated in the Mn-sensitive yeast strain Dpmr1, and
SLC30A10 was shown to be a potent Mn transporter.Material and Methods
Subjects
For clinical details see Results and Table 1. The research protocol
was approved by the West London Research Ethics Committee.
All participants provided written informed consent for participa-
tion in the study.
Homozygosity Mapping
Affected and unaffected siblings of two consanguineous families
were included in homozygosity mapping studies. For pedigrees
see Figure S1A, available online.
Total genomic DNA was extracted from whole blood of affected
individuals with the Gentra Puregene Blood Kit (QIAGEN).
Whole-genome mapping was performed with the Illumina
HumanCytoSNP-12 DNA Analysis BeadChipKit according to the
manufacturer’s instructions. SNP data were analyzed with Illu-
mina GenomeStudio Software to identify areas of homozygosity
in affected individuals. Corresponding gene lists were generated
for each area of homozygosity with the National Center for
Biotechnology Information (NCBI) genome viewer build 36.3.
Sequencing of SLC30A10
The four exons and exon-intron boundaries of the coding
sequence of SLC30A10 (NM_018713.2) were amplified by PCR
from genomic DNA (primers listed in Table S1). The amplicons
were purified with shrimp alkaline phosphatase and exonuclease
I and subsequently sequenced bidirectionally with the ABI BigDye
Terminator 1.1 system (Applied Biosystems) on an ABI DNA
sequencer. Sequence data were analyzed with the Sequencer 4.9
software (Gene Codes). Mutations were confirmed by restriction
enzyme digest test (enzymes obtained fromNew England Biolabs).
Two hundred control alleles of healthy individuals (who were,
where possible ethnicity matched) were screened by restriction
enzyme digest test or sequencing for each mutation to exclude
common variants.
Sequence Alignment and Phylogeny
Members of the SLC30A10 and Zrc1 family were identified with
Ensembl and NCBI. Sequences were aligned with ClustalW2 and
the neighbor-joined dendrogram generated with ClustalX.27 For
protein accession numbers see Table S2.
Yeast Expression Studies
Expression studies were performed with Gateway technology
(Invitrogen). AttB site-introducing primers were designed accord-
ing to the manufacturer’s instructions (Table S3). cDNA was
synthesized from human fetal liver total RNA (purchased from
Stratagene) with the SuperScript III First-Strand Synthesis System
(Invitrogen), and SLC30A10 was amplified with Platinum Pfx
DNA Polymerase (Invitrogen). Similarly, ZRC1 was amplified
from Saccharomyces cerevisiae genomic DNA (purchased from No-458 The American Journal of Human Genetics 90, 457–466, March 9vagen). The PCR products were purified with 30% PEG 8000/
30mM MgCl2.
Entry clones of SLC30A10 and ZRC1 were produced with the
pDONR221 vector and BP Clonase II enzyme mix (Invitrogen).
OneShot OmniMAX 2-T1 chemically competent Escherichia coli
cells were transformed with the BP recombination reaction and
entry clones selected on LB agar plates containing Kanamycin
(50 mg/ml). After plasmid extraction with the QIAGEN Plasmid
Mini Kit and DNA sequencing of the plasmid insert, a clone
with the correct insert sequence of SLC30A10 or ZRC1was selected
and used for site-directed mutagenesis.
Site-directed mutagenesis, with SLC30A10/pDONR221 and
ZRC1/pDONR221 as DNA templates, was performed with the
QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) ac-
cording to manufacturer’s instructions (primers are listed in Table
S4). OneShot OmniMAX 2-T1 chemically competent E. coli cells
were transformed with the mutated vectors as described above
and mutations confirmed by DNA sequencing after plasmid
extraction.
Expression clones of SLC30A10, SLC30A10 (c.266T>C [p.Leu89-
Pro]), SLC30A10 (c.585del [p.Thr196Profs*17]), ZRC1, and ZRC1
(c.131A>T [p.Asn44Ile]) were created with the pYES-DEST52
Gateway Vector and LR Clonase II enzyme mix (Invitrogen). One-
Shot OmniMAX 2-T1 chemically competent E. coli cells were
transformed and expression clones selected on LB agar plates con-
taining ampicillin (50 mg/ml). The plasmids were extracted and
used for yeast transformation. The correct sequences of the various
inserts were confirmed by DNA sequencing.
Wild-type BY4743 S. cerevisiae (Mat a/a his3D1/ his3D1 leu2D0/
leu2D0 lys2D0/þ met15D0/þ ura3D0/ ura3D0) and Dpmr1::KanMX
strains in the BY4743 background were obtained from Open
Biosystems. Yeast strains were grown on Yeast Extract Peptone
Dextrose (YPD) medium (1% yeast extract, 2% peptone, 2%
Dextrose) at 30C for 72 hr and transformed with the S.f Easy-
Comp Transformation Kit (Invitrogen). Expression clones were
selected on SC-Ura medium (0.67% yeast nitrogen base without
amino acids, 2%Dextrose and 0.13% amino acid drop-outmixture
without Uracil) at 30C. For gene expression SC-Ura induction
medium containing 20% galactose and 10% raffinose was used.
High Mn agar plates were prepared by adding MnCl2 to the
medium at the required concentrations (1M stock in H2O).Results
Clinical Characteristics of Affected Individuals
Affected individuals present at the age of 2 to 15 years with
gait disturbance and hypertonia of the limbs with some
becoming wheelchair bound. Although most cases show
pure four-limb dystonia leading to a characteristic high-
stepping gait (a ‘‘cock-walk’’ gait) and fine motor impair-
ment sometimes accompanied by dysarthria, fine tremor,
and bradykinesia, one affected individual has pure
spastic paraparesis without extrapyramidal dysfunction
(Table 1).22 Childhood developmental milestones are age-
appropriate, and intellectual development appears normal
in affected individuals; however, no formal cognitive
testing was performed. All cases have pathognomonic
MRI brain appearances with hyperintensity of globus
pallidus, putamen, caudate, subthalamic and dentate
nucleus and sparing of the thalamus and ventral pons on, 2012
Table 1. Clinical Characteristics of Individuals with a Syndrome of Hepatic Cirrhosis, Dystonia, Polycythemia, and Hypermanganesemia
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A-II-1 F 18 Punjabi (Pakistan) þ 3 6180 þ – – n/a 17.3 169 6.4 10.4 29 156 n/a
A-II-2 F 16 Punjabi (Pakistan) þ 3 3767 þ – – n/a 16.2 143 8.7 19 32 142 n/a
A-II-4 M 11 Punjabi (Pakistan) þ 5 5096 þ – – n/a 18.4 100 13.6 20 n/a 33 n/a
A-II-5 M 9 Punjabi (Pakistan) þ 5 6370 þ – þ n/a 16.7 148 5 7.46 10 85 20.4 (3.3–16.6)
B-II-2 F 12 Arabic (Yemen) þ 2 2109 þ – – n/a 20.5 n/a 8.7 30 22 246 n/a
B-II-5 F 8 Arabic (Yemen) þ 2 1636 þ – – n/a 19.1 n/a n/a n/a 26 145 n/a
B-II-7 F 4 Arabic (Yemen) þ 2 1600 þ – – n/a 18.0 n/a n/a n/a 17 40 n/a
C-II-2 F 12 Acadian (Canada) – 4 1145 þ – – – 19 114 n/a 2 12 57 n/a Brna et al.23and
Sahni et al.24
D-II-3a M y18 Arabic (United Arab
Emirates)
þ 2 n/a þ – þ þ n/a n/a n/a n/a n/a n/a n/a Tuschl21
D-II-6 F 21 Arabic (United Arab
Emirates)
þ 11 3285 þ – þ þ 18 >120 22 8 45 23 39.9 (2.5–10.5)
E-II-1 M 37 Caucasian (US) – 14 3480 – þ þ þ 22.5 116 3.7 6 normal normal 473 (0–16) Gospe22
F-II-1 F 12 Indo-Malay (Philippines) – 11 3272 þ – – n/a 21 n/a 13.1 14 23.8 72 30.2 (3.7–31.5)
G-II-1a M y25 Portuguese/ Amerindian
(Brazil)
þ 2 n/a þ – – þ n/a n/a n/a n/a n/a n/a n/a
G-II-2 F 24 Portuguese/ Amerindian
(Brazil)
þ 3 3114 þ – – þ 15.9 147 8.9 7.7 11.9 52 n/a
H-II-1 F 7 Punjabi (India) – 5 2366 þ – þ n/a 19.5 40 10.2 17.4 23 142 n/a
The following abbreviations are used: n/a, not available; TIBC, total iron binding capacity; ALT, alanine aminotransferase. Normal reference ranges are given in brackets.
aDied because of complications of cirrhosis.
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Figure 1. SLC30A10Mutations inAffectedFami-
lies with a Syndrome of Hepatic Cirrhosis, Dysto-
nia, Polycythemia, and Hypermanganesemia
(A) Mutations in SLC30A10 identified by DNA
sequencing. (For families D and G no DNA was
available for analysis of deceased siblings D-II-3
and G-II-1).
(B) Genomic structure of the exons encoding
SLC30A10 and positions of identified mutations.
The large deletion spanning exon 1 and 2 in
family A is indicated by a bracket.T1-weighted images (Figure S2). When the disease is exten-
sive, this can be accompanied by white matter and anterior
pituitary involvement. T2-weighted images also show
changes, however, to a much lesser extent, and are often
reported as normal.
Most affected individuals have liver impairment sug-
gested by raised transaminases and unconjugated hyperbi-
lirubinemia, and two individuals have died following
complications of cirrhosis (Table 1). Liver biopsies show
micronodular cirrhosis or fibrosis with positive rhodanine
staining and elevated Mn content.21,22
Whole-blood Mn levels are significantly raised in all
affected individuals (on average more than 2,000 nmol/l;
normal is less than 320 nmol/l) (Table 1), mostly to a
much higher extent than observed previously in environ-
mental Mn exposure,3,7 parenteral nutrition,10 or chronic
liver disease21 where blood levels are less than
2,000 nmol/l. Parental blood Mn levels were mildly
elevated in three families (380 to 649 nmol/l), consistent
with carrier status. These parents and heterozygous
siblings were asymptomatic and were therefore not sub-
jected to detailed evaluation of neurological and hepatic
function.
Further features generally observed in this form of in-
herited hypermanganesemia are polycythemia associated
with high erythropoietin levels and depleted iron stores
indicated by low ferritin and iron levels and increased total
iron binding capacity (Table 1).
Chelation therapy with disodium calcium edetate as rec-
ommended for environmental Mn intoxication28 has been
initiated in some individuals with improvement of neuro-
logical symptoms. Supplementation of iron, a competitive
inhibitor of intestinal Mn uptake29,30 in individuals with
low iron stores, has also proven effective to lower blood
Mn levels. A significant reduction in blood Mn levels,
normalization of the erythrocyte count, and improvement
of neurological symptoms was observed in individual460 The American Journal of Human Genetics 90, 457–466, March 9, 2012D-II-621 and G-II-2 (Figure S3). Long-term
follow-up data of manganese blood levels
is currently only available for individual
D-II-6. Combined disodium calcium ede-
tate and iron supplementation has resulted
in significant improvement of gait and fine
motor movements, resolution of polycy-themia, and normalization of liver Mn content with no
further progression of cirrhosis.21
Homozygosity Mapping Identifies a Candidate Gene
for a Syndrome of Hepatic Cirrhosis, Dystonia,
Polycythemia, and Hypermanganesemia
In order to identify shared regions of homozygosity and
potential candidate genes, DNA from the siblings of the
consanguineous families A and D were analyzed by homo-
zygosity mapping (Figure S1A). Analysis of SNP data for
family A revealed a large area of homozygosity on chromo-
somal region 1q (198.403.205 to 219.513.863 bp) shared
between all four affected siblings with the unaffected
sibling being heterozygous. Within this area there was
a region of no-call SNPs (218.057.426 to 218.158.564 bp)
consistent with a deletion. The affected sibling (D-II-6) of
family D was also homozygous in this area (217.537.040
to 219.914.224 bp) (Figure S1B and Table S5).
This area contained only one gene, SLC30A10, and this
was considered a strong candidate gene. Analysis of coordi-
nate data suggested that exons 1 and 2 of this gene were
affected by the deletion in family A.
Sanger Sequencing of SLC30A10
Sequencing of SLC30A10 in individual D-II-6 revealed a
homozygous nine base deletion in exon 1 (c.314_322del)
resulting in a deletion of three amino acids (p.Ala105_
Pro107del) (Figure S4). Both parents and three unaffected
siblings of family D were heterozygous for the mutation.
All other healthy siblings did not carry this mutation.
The sequencing data were confirmed by a restriction
enzyme digest test that used MspI (data not shown). This
mutation was absent in 200 control alleles of healthy
individuals.
Subsequent mutation analysis of SLC30A10 in a further
six families revealed homozygous sequence changes in all
affected individuals (Figure 1). Where DNA of parents
Figure 2. Evolutionary Conservation Data for SLC30A10
Putative transmembrane domains marked I–VI in gray. Positions with single, fully conserved residues are marked with an asterisk (*).
Conservation between groups of strongly and weakly similar properties is indicated by a colon (;) and a period (.), respectively. Amino
acid substitutions are marked in color: yellow, missense mutation (c.266T>C [p.Leu89Pro]); black arrows, deletion (c.298_402del,
[p.Val98_Phe134del]); blue, deletion (c.314_322del [p.Ala105_Pro107del]); green, single base deletion causing frame shift and premature
stop codon (c.585del [p.Thr196Profs*17]); pink, deletion (c.765_767del [p.Val256 del]); orange, nonsense mutation (c.922C>T
[p.Gln308*]); red, missense mutation (c.1046T>C [p.Leu349Pro]).was available, they were found to be heterozygous carriers.
None of the unaffected siblings were homozygous for the
familial mutation and mutations were absent in 200
control chromosomes of healthy unaffected individuals.
Amplification of SLC30A10 from blood, lymphoblastoid,
and fibroblast cDNA from healthy control subjects was
unsuccessful suggesting that SLC30A10 is not expressed
in these cell lines. This is consistent with previous studies
in rats showing tissue specific expression in liver, brain,
and intestine.31 Unfortunately, such tissue samples in a
form suitable for RNA analysis were not available from
affected individuals.
Sequence Alignment and Phylogeny
SLC30A10 sequence alignment of various species with its
ortholog in fungi, Zrc1, confirmed that all identified amino
acid substitutions affect evolutionary highly conservedThe Ameareas of the protein (Figure 2). The phylogeny tree shows
the two distinct evolutionary groups of SLC30A10 and
Zrc1 (Figure S5).
Yeast Expression Studies
The function of human wild-type SLC30A10 and the effect
of mutations were investigated in the Mn-sensitive Dpmr1
yeast strain. PMR1 (plasma membrane ATPase-related)
encodes a P-type Ca2þ/Mn2þ ATPase located at the Golgi
membrane that is involved in the transport of Mn2þ
from the cytosol into the Golgi. Thereby, it plays an impor-
tant role in the regulation of cellular Mn2þ homeostasis in
yeast. Deletion of PMR1 leads to accumulation of Mn2þ in
the cytosol and increased sensitivity of cells to high
concentrations of Mn2þ in the growth medium.32–34
Out of the eight identified mutations, we chose to in-
vestigate two different types of sequence changes: onerican Journal of Human Genetics 90, 457–466, March 9, 2012 461
Figure 3. Yeast Expression Studies
Wild-type cells BY4743 and Dpmr1 cells were transformed with empty vector pYES-Dest52, SLC30A10, SLC30A10 (c.266T>C [p.Leu89-
Pro]), SLC30A10 (c.585del [p.Thr196Profs*17]), ZRC1, and ZRC1 (c.131A>T [p.Asn44Ile]). 105, 5 3 104, 104, 5 3 103 and 103 cells (a–e)
were spotted onto SC-Ura plates supplemented with or without 1.5 mM MnCl2 and incubated at 30
C for 6 days. Human SLC30A10
rescues growth of the manganese-sensitive Dpmr1 yeast strain on SC-Ura medium supplemented with high manganese concentration.
Introducing themissensemutation (c.266T>C [p.Leu89Pro]) or nonsensemutation (c.585del [p.Thr196Profs*17]) by site-directedmuta-
genesis abolishes the effect.missense mutation (c.266T>C), which is located in a
highly conserved transmembrane region, and one non-
sense mutation (c.585del) predicted to lead to the produc-
tion of a significantly truncated protein of 213 amino acids
(p.Thr196Profs*17; Figure 2). Both mutations were created
with site-directedmutagenesis. ZRC1, the yeast ortholog of
SLC30A10, and ZRC1 with its previously described Mn
resistant mutation (c.131A>T) were used as controls.32
The Dpmr1 yeast strain failed to grow on SC-Ura medium
supplemented with a high Mn concentration (1.5 mM
MnCl2) (Figure 3). Overexpression of the wild-type human
SLC30A10 inserted into the yeast expression vector pYES-
DEST52 under the control of the GAL1 promoter restored
growth under high Mn concentrations suggesting its
crucial role in Mn transport. The presence of the missense
(c.266T>C) and nonsense (c.585del) mutation in
SLC30A10 abolished growth (Figure 3).Discussion
We have identified the genetic basis of an inborn error of
Mn homeostasis with accumulation of Mn in the liver
and basal ganglia; it is caused by mutations in SLC30A10.
Human SLC30A10 is on chromosome 1 and has four
exons that encode a protein of 485 amino acids
(NP_061183.2) (Figure 1). This gene was recently identified
by bioinformatics methods and was classified as a member
of the SLC30 solute carrier subfamily of the cation diffu-
sion facilitator (CDF) family.35 To date the SLC30 family
has been thought to be a group of mammalian Zn trans-
porters.35,36 Proteins of this family have a conserved
structure of six transmembrane helices (TMD I–VI) with
both N and C termini located on the cytoplasmic side of462 The American Journal of Human Genetics 90, 457–466, March 9the plasma membrane.35,37 Solute carriers are secondary
active transporters allowingmovement ofmolecules across
a cell membrane against a concentration gradient without
the direct use of ATP. Members of this family are found in
all biological kingdoms and transfer metals out of the
cytosol, either extracellularly or into organelles, thereby
regulating intracellular metal concentrations.31,35–38
Mutation analysis of SLC30A10 revealed homozygous
sequence changes in all affected individuals described.
These are predicted to either cause a significantly truncated
protein because of a frameshift and premature stop codon
or are deletions or affect an evolutionary highly conserved
area of the protein and are therefore likely to have a detri-
mental effect on protein function (Figure 2). All identified
sequence changes were absent in 200 control chromo-
somes of healthy individuals and are not listed as SNPs
on dbSNP and Ensembl databases. Analysis of variants in
the general population reported on dbSNP and Ensembl
identified two SNPs in the coding region of SLC30A10
that are predicted by the bioinformatic tools PolyPhen
and SIFT to be damaging to protein function (Table S6).
However, both are rare in the general population, 1:4,551
and 1:4,548, respectively. It will be of interest to study
these variants and establish whether they are pathological
mutations.
The deleterious effects of mutations in this gene were
confirmed by expression studies in the Mn-sensitive
Dpmr1 yeast strain. Although wild-type SLC30A10 restored
growth in high Mn concentrations, SLC30A10 carrying
a missense (c.266T>C) or nonsense (c.585del) mutation
did not (Figure 3). Not very surprisingly, the effect of
human wild-type SLC30A10 in yeast was less pronounced
than that of ZRC1 carrying the Mn resistance mutation
(c.131A>T). SLC30A10 and Zrc1 (p.Asn44Ile) probably, 2012
Table 2. Comparison of Conserved Amino Acid Residues in Zrc1,
which When Substituted Confer Resistance to High Manganese
Toxicity, with Conserved Residues Present in SLC30A10
Amino Acid Positiona
Zrc1
(n ¼ 5)
SLC30A10
(n ¼ 43)
33 Leucine Isoleucineb
40 Phenylalanine Phenylalanine
44 Asparagine Serine
52 Alanine Glycine
79 Glycine Glycine
86 Phenylalanine Phenylalanine
87 Leucine Leucine
101 Arginine Arginine
272 Serine Threonine
275 Isoleucine Methioninec
n is used as an abbreviation for the number of genes used for alignment. High-
lighted residues are conserved in Zrc1 and SLC30A10 but are not conserved
between the two groups.
aResidues compared are those reported to be gain-of-function mutations in
ZRC1 that determine metal specificity.33,41 Numbering relative to
S. cerevisiae Zrc1.
bValine in zebrafish.
cPhenylalanine in zebrafish.both contribute to Mn uptake into vacuolar vesicles; how
this actually occurs and whether there are different mech-
anisms involved has yet to be determined.
Our studies demonstrate that human wild-type
SLC30A10 functions as a Mn transporter that protects cells
from Mn toxicity. Amino acid substitutions in the
SLC30A10 yeast ortholog Zrc1 have recently been reported
to alter substrate specificity from Zn to iron and Mn.33
Evolutionary changes in the amino acid sequence might
be responsible for the altered metal affinity in man.
CDF transporters share a high degree of sequence conser-
vation in the charged residues of TMD II and V that are
thought to function as specific metal binding sites. Zn
binding in YiiP, an E. coli CDF member, is facilitated by
two highly conserved aspartic acid residues (position 45
and 49) in TMD II and a histidine and aspartic acid (posi-
tion 153 and 157) in TMD V.39,40 Several residues within
TMD II, III, and IV of Zrc1 are also known to be critical
for zinc specificity33,41 Alignment of the protein sequences
of Zrc1 and SLC30A10 from different species revealed
that during evolution Leu33, Asn44, and Ala52 in TMD
II and Ser272 and Ile275 in TMD IV have been replaced
by Ile, Ser, Gly, The, and Met in SLC30A10, respectively
(Table 2).41 These amino acids appear to be highly
conserved throughout the SLC30A10 family. Lack of
conservation of these amino acids between Zrc1 and
SLC30A10 suggests that they have evolved independently
and functionally as two different transporters. The Zrc1
subfamily contains mostly prokaryotic members from
both eubacterial and archaeal sources, whereas the
SLC30A10 subfamily contains eukaryotic members
(Figure S5). Therefore, we conclude that evolutionaryThe Amechanges in the amino acid sequence of the protein have
altered the substrate specificity of the transporter from
Zn in yeast to Mn in mammalian cells. This is consistent
with the finding that affected individuals carrying a muta-
tion in SLC30A10 have high blood Mn levels, whereas Zn
levels are normal. Although we have not excluded the
possibility that SLC30A10 might be involved in the trans-
port of other divalent cations, the mutations that we have
encountered in this gene only result in a hypermanganese-
mia phenotype and other blood cation levels are within
the normal range. Further studies are required to investi-
gate the properties of SLC30A10 and determine how
SLC30A10 is involved in the regulation of Mn transport.
Mn homeostasis in higher organisms is not well under-
stood. Various cellular uptake mechanisms for Mn have
been suggested, including divalent metal transporter
(DMT1), ZIP-8, the transferrin (Tf)/Tf receptor (TfR)
system, voltage and store operated calcium channels, and
the glutamate receptor channel; however, none of these
transporters are specific for Mn.1,42,43 Given that muta-
tions in SLC30A10 in humans have a detrimental effect
on Mn homeostasis, we expect that SLC30A10 is a key
player in Mn transport.
Neurological presentation of individuals with a syn-
drome of hepatic cirrhosis, dystonia, polycythemia,
and hypermanganesemia resembles environmental Mn
toxicity and AHD, both presenting with atypical parkin-
sonism that is poorly responsive to L-Dopa treat-
ment.3,6,14,15 Although dystonia and rigidity are more
prominent in inherited hypermanganesemia and environ-
mental manganism, AHD is more likely to cause ataxia and
chorea.14 Dysarthria can be a feature in all three forms
of hypermanganesemia. Occupational manganism can
present with psychosis and compulsive behaviors, so-
called ‘‘Mn madness.’’5 Cognitive and behavioral changes
have not been observed in inherited hypermanganesemia.
MRI brain findings of affected individuals are similar
to those seen in environmental Mn toxicity and AHD
(Figure S2).4,14,15 The most characteristic finding in in-
herited hypermanganesemia is increased signal intensity
of the globus pallidus on T1-weighted sequences with
changes extending into adjacent basal ganglia in most
cases. When the disease is extensive, white matter involve-
ment can be observed. More frequently than seen in occu-
pational manganism and AHD, T2 changes of low signal
return from the globus pallidus are also present in in-
herited hypermanganesemia. However, there are no
specific MRI features that can distinguish SLC30A10 muta-
tions from acquired causes of hypermanganesemia.
One affected individual has a different neurological
phenotype of spastic paraparesis without extrapyramidal
motor impairment.22 This presentation is similar to
hepatic myelopathy, a rare complication of hepatic failure
that has also been attributed to Mn accumulation.44 In
both cases, MRI of the spinal cord is normal.
Although cirrhosis has not been observed in environ-
mental Mn exposure, it is the life-limiting factor in thisrican Journal of Human Genetics 90, 457–466, March 9, 2012 463
form of inherited hypermanganesemia. The liver is the
major organ involved in the excretion of Mn via the bile.
In animal models increased exposure to Mn results in
hepatocellular necrosis and elevated transaminases.45,46
Polycythemia and depleted iron stores are hallmarks of
this disease and should prompt SLC30A10 analysis. Both
features have not been observed in cases of environmental
Mn toxicity and AHD. Individuals with a diagnosis of
cryptogenic liver cirrhosis and AHD should be carefully
assessed for these features to allow correct diagnosis. Mn
has been suggested to induce erythropoietin gene expres-
sion,47 and this is the likely mechanism behind the
development of polycythemia in affected individuals.
Homeostatic regulation of Mn and iron is closely linked
and explains the depleted iron stores in affected individ-
uals.1,29,42,48 Mn has a direct effect on the availability of
the bioactive iron pool and induces an iron-starved pheno-
type with reduced ferritin expression and increased TfR
expression. With increasing exposure to Mn, release of
iron from intracellular stores, enhanced iron uptake, and
decreased iron utilization is favored.49,50 Iron and Mn are
chemically and structurally similar and compete for the
same serum binding protein (Tf) and membranous trans-
porter protein (DMT1). Therefore, dietary iron status has
a direct effect on Mn uptake.29,30 This explains the benefi-
cial effect of iron supplementation in affected individuals.
Chelation therapy to enhance urinary Mn excretion has
been attempted with various chelation agents. Disodium
calcium edetate as recommended for environmental Mn
intoxication28 has significantly improved neurological
symptoms in some subjects, led to reduction of blood
Mn, and halted the progression of cirrhosis.21 It carries
the disadvantage of intravenous application over 5 days
every 4 weeks and the requirement of strict monitoring
of other essential heavy metals such as zinc, copper, and
selenium.51 Several of the affected individuals are from
countries with poor medical resources where intravenous
disodium calcium edetate is either not available or the
current setting would not allow for frequent application
and monitoring of chelation therapy. Other chelating
agents have therefore been used. Two siblings (B-II-2 and
B-II-5) have improved clinically on oral dimercaptosuc-
cinic acid (DMSA). However, because both siblings also
receive iron supplementation, it is difficult to attribute
the effect to one or the other. Blood and urine Mn levels
and neurological symptoms of twomen with occupational
Mn intoxication did not respond significantly to DMSA
treatment.52 Para-aminosalicylic acid has also been re-
ported not to be beneficial.23 Further research is required
to identify specific and efficacious treatment agents for hy-
permanganesemia that can be administered conveniently,
preferably by mouth.
Chronic exposure to Mn has been suggested to be
involved in the pathogenesis of PD.53–57 Whole-blood
Mn levels in a PD cohort have been found to be signifi-
cantly higher than in healthy control subjects.55 Also,
individuals affected by early onset forms of idiopathic PD464 The American Journal of Human Genetics 90, 457–466, March 9with mutations in PARK2 [MIM 602544] (Juvenile Parkin-
son’s Disease type 2 [MIM 600116]), and ATP13A2 [MIM
610513] (Kufor Rakeb Syndrome [MIM 606693]) seem to
be at higher risk of Mn toxicity.56,57 Therefore, the impor-
tance of understanding Mn homeostasis in more detail is
becoming increasingly evident.
In summary, by studying a rare syndrome of inherited
Mn accumulation, we have identified a unique Mn trans-
porter in man. SLC30A10 has been shown to function as
a specific Mn transporter in higher organisms and when
mutated causes a syndrome of hepatic cirrhosis, dystonia,
polycythemia, and hypermanganesemia characterized by
accumulation of Mn in liver and brain.Supplemental Data
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